FASENRA® Subcutaneous Injection 30 mg / 10mg Syringe Post-Marketing Study for Pediatric Patients with Bronchial Asthma

What this Trial Is About

This research aims to evaluate the real-world use of Fasenra® Subcutaneous Injection 30 mg / 10 mg Syringe in children with bronchial asthma who have not responded to existing treatments. The study focuses on monitoring the development of unexpected adverse events that may be related to the drug, as well as tracking known adverse events in a post-marketing setting. Additionally, the study will assess the drug's effectiveness in improving lung function and asthma control. Participants in this observational study are children aged 6 to under 15 years who are receiving Fasenra for the first time due to difficult-to-control bronchial asthma. There is no intervention or randomization involved since this is a post-marketing surveillance study. The study will collect data during regular treatment and follow-up visits as the drug is used in typical clinical practice. Participants will be monitored for up to one year to record any adverse drug reactions and to evaluate asthma control and pulmonary function. The main outcome measured is the incidence of adverse drug reactions from the start of treatment through one year. Researchers will gather information from medical records and routine clinical assessments to understand the drug’s safety and effectiveness over this period.

Fasenra Pediatric Japan Post-Marketing Study(PMS)